^
    Back
    Association details:
    Biomarker:BRAF V600E + TERT E441del + RET N579K + EZH2 D154E + CDK4 S259L
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Investig Med
    Title:

    Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer

    Excerpt:
    We report a case of aggressive ATC with 5 sequence mutations: BRAF V600E (mutation fraction [MF] 34%), TERT E441del (MF 37%), RET N579K (MF 55%), EZH2 D154E (MF 60%), and CDK4 S259L (MF 48%). The patient had a dramatic response to the Dab/Tram combination with near complete resolution...
    DOI:
    10.1155/2019/4121234